Talk to the Institute
Published mark

Dyne Therapeutics, Inc.

NASDAQ: DYN. Canonical company identity and public leadership record.

US

Record source reportedRecord not claimedNo Eval published
Follow companySave PDF
Alpha ID
alpha:company:39fcbb27-6dcb-41c6-96d6-74d5b66d97d2
SEC CIK
0001818794
Record version
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 19, 2026
Newest evidence
Apr 23, 2026
Monitoring
Not yet monitored Details
Integrity
Not yet signed Methodology
CEO
Jeremy K. CoxSince Apr 23, 2026
Chair
Jason Rhodes
Independent
Not published8 directors published
Published claims
212 distinct sources
Evidence records
60 pinned
Source conflicts
0None open

Built from 2 distinct sources and 6 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.

CorroboratedSource reportedAlpha inferenceNot disclosed

Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works

DIRECTOR APPOINTED

Johanna Friedl-Naderer seat on Dyne Therapeutics, Inc., effective 2026-04-23.

EffectiveEffective Apr 23, 2026E3

Monitoring

Continuous

What the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.

  • Identityunclaimed
    Published
  • Evidencesource_reported
    Published
  • Evaluationnot_evaluated
    Published
  • MonitoringNot yet published for this record.
    Not published
  • AuthorityNot yet published for this record.
    Not published
  • Freshnesscurrent
    Published

Leadership

Evidence
RolePersonSinceStatusClaim
Chief Executive Officer, President and DirectorJeremy K. CoxApr 2026currentSource reportedE4
Chief Innovation OfficerOxana BeskrovnayaApr 2026currentSource reportedE5
Senior Vice President, Head of Finance and AdministrationRichard ScalzoApr 2026currentSource reportedE6
Chief Medical OfficerDouglas KerrNot capturedunknownSource reportedE2
Chief Financial Officer and TreasurerErick LuceraNot capturedunknownSource reportedE2
Chief Commercial OfficerJohanna Friedl-NadererNot capturedunknownSource reportedE2
Chief Executive Officer and PresidentJohn G. CoxNot capturedunknownSource reportedE2

Board of directors

Evidence

8 directors published. Independence determinations are not published for every director.

DirectorStatusSinceCommitteesClaim
Brian PosnerIndependence not published2025None publishedSource reportedE3
Carlo IncertiIndependence not published2022None publishedSource reportedE3
Catherine Stehman-BreenIndependence not published2019None publishedSource reportedE3
David LubnerIndependence not published2020None publishedSource reportedE3
Dirk KerstenIndependence not published2018None publishedSource reportedE3
Edward HurwitzIndependence not published2018None publishedSource reportedE3
Johanna Friedl-NadererIndependence not published2026None publishedSource reportedE3
Vikram KarnaniIndependence not published2025None publishedSource reportedE3
Jason RhodesIndependentChairNot publishedNone publishedSource reportedE2
John G. CoxNot independentNot publishedPresident and DirectorSource reportedE2

Committees and risk ownership

Evidence
CommitteeChairMembersRisks assigned
President and DirectorNot publishedJohn G. CoxNot described in the published record

Control and voting power

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Authority to act

Evidence and agent registry

Who can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.

Principal executive officerJeremy K. Cox, Chief Executive Officer, President and Director, from Apr 23, 2026
Source reportedE4
company:39fcbb27-6dcb-41c6-96d6-74d5b66d97d2:leadership_role:17
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
bind
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
agents
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
delegations

Financials and market context

Evidence
Security ListingDYN (NASDAQ)
Source reportedE1
company:39fcbb27-6dcb-41c6-96d6-74d5b66d97d2:security_listing:22
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 19, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.

Governance and policies

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Risk, audit, and cyber

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

AI oversight and accountability

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Compensation

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Other published claims

Evidence

Published Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.

Legal NameDyne Therapeutics, Inc.
Source reportedE1
company:39fcbb27-6dcb-41c6-96d6-74d5b66d97d2:legal_name:1
Entity StatusPublic listing published
Source reportedE1
company:39fcbb27-6dcb-41c6-96d6-74d5b66d97d2:entity_status:3

Not yet in this record

Coverage

A gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.

  • Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
  • OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
  • FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
  • CompensationNot reviewed. Pay design shows how incentives are governed.
  • GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
  • Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
  • AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
  • LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
  • RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
  • CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
  • AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
  • Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
  • Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
  • Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
  • Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
  • Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
  • This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.

Subject and corrections

Public-role doctrine

This record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.

Basis
Published company record built from public sources
Sources
6 evidence records cited. 0 with redistribution rights.
Never published
Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
Record claimed
No
Open disputes
0
Identity ownership
unclaimed
Claiming not yet available

If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.

Evidence

Authority and rights
  1. E1
    Alpha canonical company public projection
    Alpha canonical company public projection. canonical identity. Retrieved Oct 19, 2026. Cited by 4 Claims.
    Open web
    Rights not recorded, link only
    Evidence not pinned
  2. E2
    SEC DEF 14A 0001193125-26-173655
    sec def 14a. Published Apr 23, 2026. Retrieved Sep 6, 2026. Cited by 6 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  3. E3
    DEF 14A dyn-20260422.htm
    sec proxy. Published Apr 23, 2026. Retrieved Sep 2, 2026. Cited by 8 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  4. E4
    DYN DEF 14A executive officers
    sec filing. Published Apr 23, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  5. E5
    DYN DEF 14A executive officers
    sec filing. Published Apr 23, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  6. E6
    DYN DEF 14A executive officers
    sec filing. Published Apr 23, 2026. Retrieved May 16, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned

What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 19, 2026
  • Johanna Friedl-Naderer seat on Dyne Therapeutics, Inc., effective 2026-04-23.
  • Jeremy K. Cox executive of Dyne Therapeutics, Inc., effective 2026-04-23.
  • Oxana Beskrovnaya executive of Dyne Therapeutics, Inc., effective 2026-04-23.
  • Richard Scalzo executive of Dyne Therapeutics, Inc., effective 2026-04-23.
  • Brian Posner seat on Dyne Therapeutics, Inc., effective 2025-01-01.
  • Vikram Karnani seat on Dyne Therapeutics, Inc., effective 2025-01-01.
  • Carlo Incerti seat on Dyne Therapeutics, Inc., effective 2022-01-01.
  • David Lubner seat on Dyne Therapeutics, Inc., effective 2020-01-01.
  • Catherine Stehman-Breen seat on Dyne Therapeutics, Inc., effective 2019-01-01.
  • Dirk Kersten seat on Dyne Therapeutics, Inc., effective 2018-01-01.
  • Edward Hurwitz seat on Dyne Therapeutics, Inc., effective 2018-01-01.
Appearance

Alpha Governance PBC. The Registry records reported facts and Alpha's assessments separately. A missing fact is not evidence that it is false.

Record alpha:company:39fcbb27-6dcb-41c6-96d6-74d5b66d97d2, version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce. https://registry.alpha.ac/companies/dyne-therapeutics-inc

Navigate

On this record

  1. Overview
  2. Monitoring4
  3. Leadership7
  4. Board10
  5. Committees1
  6. Control and voting0
  7. Authority to act4
  8. Financials1
  9. Governance0
  10. Risk0
  11. AI oversight0
  12. Legal0
  13. Compensation0
  14. Other published claims3
  15. Coverage gaps17
  16. Linked people15
  17. Subject and corrections6
  18. Evidence6
  19. Version historyvpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

Linked records

Registry

Appearance

esc
  • Actions
    Switch to agent viewJSON, Markdown, MCP
  • Copy Alpha IDalpha:company:39fcbb27-6dcb-41c6-96d6-74d5b66d97d2
  • Cite this recordDyne Therapeutics, Inc.
  • Copy canonical URLregistry.alpha.ac/companies/dyne-therapeutics-inc
  • Copy as MarkdownWith assertion states
  • Report an error
  • Theme: System
  • Theme: Light
  • Theme: Dark
  • Records
    Dyne Therapeutics, Inc.Company
  • Jeremy K. CoxPerson
  • Oxana BeskrovnayaPerson
  • Richard ScalzoPerson
  • Douglas KerrPerson
  • Erick LuceraPerson
  • Johanna Friedl-NadererPerson
  • John G. CoxPerson
  • Brian PosnerPerson
  • Carlo IncertiPerson
  • Catherine Stehman-BreenPerson
  • David LubnerPerson
  • Dirk KerstenPerson
  • Edward HurwitzPerson
  • Vikram KarnaniPerson
  • Jason RhodesPerson
  • Sections
    OverviewDyne Therapeutics, Inc.
  • MonitoringDyne Therapeutics, Inc.
  • LeadershipDyne Therapeutics, Inc.
  • BoardDyne Therapeutics, Inc.
  • CommitteesDyne Therapeutics, Inc.
  • Control and votingDyne Therapeutics, Inc.
  • Authority to actDyne Therapeutics, Inc.
  • FinancialsDyne Therapeutics, Inc.
  • GovernanceDyne Therapeutics, Inc.
  • RiskDyne Therapeutics, Inc.
  • AI oversightDyne Therapeutics, Inc.
  • LegalDyne Therapeutics, Inc.
  • CompensationDyne Therapeutics, Inc.
  • Other published claimsDyne Therapeutics, Inc.
  • Coverage gapsDyne Therapeutics, Inc.
↑ ↓ move↵ openThis record only

Report an error

Reports attach to the Claim and go to an Alpha analyst through the correction form. Corrections are versioned, and the original stays in history.